Ulcerative colitis: From inflammation to cancer. Do estrogen receptors have a role?

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11496-11504

  Principi, Mariabeatrice ^a   Barone, Michele ^b   Pricci, Maria ^a   De Tullio, Nicola ^a   Losurdo, Giuseppe ^a   Ierardi, Enzo ^a   Di Leo, Alfredo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Chemoprevention; Colorectal cancer; Dietary supplementation; Epithelial dysplasia; Estrogen receptors; Inflammatory bowel disease; Phytoestrogens; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESALAZINE; PHYTOESTROGEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; DIET SUPPLEMENTATION; DISEASE COURSE; HUMAN; PROTEIN EXPRESSION; ULCERATIVE COLITIS; AGONISTS; ANIMAL; CELL TRANSFORMATION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; METABOLISM; PROTECTION; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; ESTROGEN RECEPTOR BETA; HUMANS; PHYTOESTROGENS; PROTECTIVE FACTORS; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84909647856     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11496     Document Type: Article

References (95)

1. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012; 3: 107 [PMID: 22586430 DOI: 10.3389/fimmu.2012.00107]
2. Lakatos PL, Lakatos L. Challenges in calculating the risk for colorectal cancer in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 1179; author reply 1179-1180 [PMID: 22610004 DOI: 10.1016/j.cgh.2012.04.021]
3. Katsanos KH, Stamou P, Tatsioni A, Tsianos VE, Zoumbas S, Kavvadia S, Giga A, Vagias I, Christodoulou DK, Tsianos EV. Prevalence of inflammatory bowel disease related dysplasia and cancer in 1500 colonoscopies from a referral center in northwestern Greece. J Crohns Colitis 2011; 5: 19-23 [PMID: 21272799 DOI: 10.1016/j.crohns.2010.09.001]
4. Castańo-Milla C, Chaparro M, Gisbert JP. Has the risk of developing colorectal cancer in patients with ulcerative colitis been overstated? A meta-analysis. Gastroenterology 2012; 142: S-251
5. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]
6. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381.e1; quiz e13-14 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]
7. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
8. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233 [PMID: 2215606 DOI: 10.1056/NEJM199011013231802]
9. Baars JE, Kuipers EJ, van Haastert M, Nicolaï JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, longterm survey. J Gastroenterol 2012; 47: 1308-1322 [PMID: 22627504 DOI: 10.1007/s00535-012-0603-2]
10. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-1362 [PMID: 11313305 DOI: 10.1053/gast.2001.24052]
11. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]
12. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816 [PMID: 15542520 DOI: 10.1136/gut.2003.038505]
13. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105; quiz 1340-1341 [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001]
14. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol 2011; 17: 3092-3100 [PMID: 21912451 DOI: 10.3748/wjg.v17.i26.3092]
15. Talero E, Sánchez-Fidalgo S, Villegas I, de la Lastra CA, Illanes M, Motilva V. Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 2011; 17: 696-710 [PMID: 20722052 DOI: 10.1002/ibd.21420]
16. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-588 [PMID: 10802717 DOI: 10.1038/75068]
17. Stolfi C, Rizzo A, Franzè E, Rotondi A, Fantini MC, Sarra M, Caruso R, Monteleone I, Sileri P, Franceschilli L, Caprioli F, Ferrero S, MacDonald TT, Pallone F, Monteleone G. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 2011; 208: 2279-2290 [PMID: 21987656 DOI: 10.1084/jem.20111106]
18. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, Egashira K, Mukaida N. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009; 69: 7884-7892 [PMID: 19773434 DOI: 10.1158/0008-5472.CAN-09-1451]
19. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045 [PMID: 19890111 DOI: 10.1056/NEJMoa0907206]
20. Galatola M, Miele E, Strisciuglio C, Paparo L, Rega D, Delrio P, Duraturo F, Martinelli M, Rossi GB, Staiano A, Izzo P, De Rosa M. Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J Gastroenterol 2013; 19: 8659-8670 [PMID: 24379584 DOI: 10.3748/wjg.v19.i46.8659]
21. Becker C, Fantini MC, Neurath MF. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 2006; 17: 97-106 [PMID: 16298544 DOI: 10.1016/j.cytogfr.2005.09.004]
22. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127 [PMID: 17615359 DOI: 10.1126/science.1140488]
23. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008; 27: 234-243 [PMID: 18176605 DOI: 10.1038/sj.onc.1210908]
24. Harpaz N, Ward SC, Mescoli C, Itzkowitz SH, Polydorides AD. Precancerous lesions in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2013; 27: 257-267 [PMID: 23809244 DOI: 10.1016/j.bpg.2013.03.014]
25. Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF, Shepherd NA, Novelli MR, Jankowski JA, Wright NA. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 2009; 136: 542-550.e6 [PMID: 19103203 DOI: 10.1053/j.gastro.2008.10.086]
26. Gerrits MM, Chen M, Theeuwes M, van Dekken H, Sikkema M, Steyerberg EW, Lingsma HF, Siersema PD, Xia B, Kusters JG, van der Woude CJ, Kuipers EJ. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol (Dordr) 2011; 34: 107-117 [PMID: 21327897 DOI: 10.1007/s13402-010-0006-4]
27. Pozza A, Scarpa M, Ruffolo C, Polese L, Erroi F, Bridda A, Norberto L, Frego M. Colonic carcinogenesis in IBD: molecular events. Ann Ital Chir 2011; 82: 19-28 [PMID: 21657151]
28. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000; 321: 886-889 [PMID: 11021873 DOI: 10.1136/bmj.321.7265.886]
29. Tanaka T. Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Int J Inflam 2012; 2012: 658786 [PMID: 22518340 DOI: 10.1155/2012/658786]
30. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7: 827-851 [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001]
31. Ierardi E, Principi M, Francavilla R, Passaro S, Noviello F, Burattini O, Francavilla A. Epithelial proliferation and ras p21 oncoprotein expression in rectal mucosa of patients with ulcerative colitis. Dig Dis Sci 2001; 46: 1083-1087 [PMID: 11341653]
32. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]
33. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-774, 774.e1-4; quiz e12-13 [PMID: 20141809 DOI: 10.1053/j.gastro.2009.12.035]
34. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804]
35. van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol 2009; 15: 226-230 [PMID: 19132774 DOI: 10.3748/wjg.15.226]
36. Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol 2012; 18: 3823-3827 [PMID: 22876033 DOI: 10.3748/wjg.v18.i29.3823]
37. de Dombal FT. Ulcerative colitis. Epidemiology and aetiology, course and prognosis. Br Med J 1971; 1: 649-650 [PMID: 4926950 DOI: 10.1136/bmj.1.5750.649]
38. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-211 [PMID: 16534422 DOI: 10.1097/01.MIB.0000217770.21261.ce]
39. Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol 2013; 19: 7561-7568 [PMID: 24282346 DOI: 10.3748/wjg.v19.i43.7561]
40. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001; 63: 165-192 [PMID: 11181953 DOI: 10.1146/annurev.physiol.63.1.165]
41. Messa C, Russo F, Pricci M, Di Leo A. Epidermal growth factor and 17beta-estradiol effects on proliferation of a human gastric cancer cell line (AGS). Scand J Gastroenterol 2000; 35: 753-758 [PMID: 10972181 DOI: 10.1080/003655200750023444]
42. Jensen EV, DeSombre ER. Mechanism of action of the female sex hormones. Annu Rev Biochem 1972; 41: 203-230 [PMID: 4563437 DOI: 10.1146/annurev.bi.41.070172.001223]
43. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53 [PMID: 8769313 DOI: 10.1016/0014-5793(96)00782-X]
44. Couse JF, Curtis Hewitt S, Korach KS. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 2000; 74: 287-296 [PMID: 11162937 DOI: 10.1016/S0960-0760(00)00105-9]
45. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-5578 [PMID: 10579320]
46. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Pestell RG, Kushner PJ. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002; 277: 24353-24360 [PMID: 11986316 DOI: 10.1074/jbc.M201829200]
47. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423-428 [PMID: 14729654 DOI: 10.1158/0008-5472.CAN-03-2446]
48. Barone M, Lofano K, De Tullio N, Licinio R, Albano F, Di Leo A. Dietary, endocrine, and metabolic factors in the development of colorectal cancer. J Gastrointest Cancer 2012; 43: 13-19 [PMID: 22045273 DOI: 10.1007/s12029-011-9332-7]
49. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537-551 [PMID: 15369453 DOI: 10.1677/erc.1.00800]
50. Koo JH, Leong RW. Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. J Gastroenterol Hepatol 2010; 25: 33-42 [PMID: 19874446 DOI: 10.1111/j.1440-1746.2009.05992.x]
51. Woodson K, Lanza E, Tangrea JA, Albert PS, Slattery M, Pinsky J, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin A. Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst 2001; 93: 1799-1805 [PMID: 11734596 DOI: 10.1093/jnci/93.23.1799]
52. Solimando R, Bazzoli F, Ricciardiello L. Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment? Best Pract Res Clin Gastroenterol 2011; 25: 555-568 [PMID: 22122771 DOI: 10.1016/j.bpg.2011.09.004]
53. American Cancer Society. Cancer fact figures. American Cancer Society, Atlanta 1995. Available from: URL: http://www.cancer.org/search/index?QueryText=Cancer fact figures
54. Francavilla A, Di Leo A, Polimeno L, Conte D, Barone M, Fanizza G, Chiumarulo C, Rizzo G, Rubino M. Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue. Gastroenterology 1987; 93: 1301-1306 [PMID: 3678749]
55. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 1251-1258 [PMID: 12763213 DOI: 10.1016/S0959-8049(03)00239-9]
56. Di Leo A, Barone M, Maiorano E, Tanzi S, Piscitelli D, Marangi S, Lofano K, Ierardi E, Principi M, Francavilla A. ERbeta expression in large bowel adenomas: implications in colon carcinogenesis. Dig Liver Dis 2008; 40: 260-266 [PMID: 18093886 DOI: 10.1016/j.dld.2007.10.018]
57. Barone M, Scavo MP, Papagni S, Piscitelli D, Guido R, Di Lena M, Comelli MC, Di Leo A. ERβ expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. Scand J Gastroenterol 2010; 45: 1320-1328 [PMID: 20446826 DOI: 10.3109/00365521.2010.487915]
58. Di Leo A, Messa C, Russo F, Misciagna G, Guerra V, Taveri R, Leo S. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci 1994; 39: 2038-2042 [PMID: 8082515 DOI: 10.1007/BF02088144]
59. Barone M, Tanzi S, Lofano K, Scavo MP, Guido R, Demarinis L, Principi MB, Bucci A, Di Leo A. Estrogens, phytoestrogens and colorectal neoproliferative lesions. Genes Nutr 2008; 3: 7-13 [PMID: 18850193 DOI: 10.1007/s12263-008-0081-6]
60. Harnish DC, Albert LM, Leathurby Y, Eckert AM, Ciarletta A, Kasaian M, Keith JC. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G118-G125 [PMID: 12958017 DOI: 10.1152/ajpgi.00024.2003]
61. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008; 9: 385-391 [PMID: 18374292 DOI: 10.1016/S1470-2045(08)70100-1]
62. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-973 [PMID: 14611673 DOI: 10.1111/j.1349-7006.2003.tb01386.x]
63. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog 2011; 10: 9 [PMID: 21483655 DOI: 10.4103/1477-3163.78279]
64. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-β protects against colitis-associated neoplasia in mice. Int J Cancer 2012; 131: 2553-2561 [PMID: 22488198 DOI: 10.1002/ijc.27578]
65. Fujii S, Tominaga K, Kitajima K, Takeda J, Kusaka T, Fujita M, Ichikawa K, Tomita S, Ohkura Y, Ono Y, Imura J, Chiba T, Fujimori T. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 2005; 54: 1287-1292 [PMID: 15870230 DOI: 10.1136/gut.2004.062059]
66. Tominaga K, Fujii S, Mukawa K, Fujita M, Ichikawa K, Tomita S, Imai Y, Kanke K, Ono Y, Terano A, Hiraishi H, Fujimori T. Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in non-neoplastic epithelium from patients with ulcerative colitis. Clin Cancer Res 2005; 11: 8880-8885 [PMID: 16361578 DOI: 10.1158/1078-0432.CCR-05-1309]
67. Principi M, De Tullio N, Scavo MP, Piscitelli D, Marzullo A, Russo S, Albano F, Lofano K, Papagni S, Barone M, Ierardi E, Di Leo A. Estrogen receptors expression in long-lasting ulcerative pancolitis with and without dysplasia: a preliminary report. Scand J Gastroenterol 2012; 47: 1253-1254 [PMID: 22571385 DOI: 10.3109/00365521.2012.685757]
68. Principi M, Scavo MP, Piscitelli D, Villanacci V, Contaldo A, Neve V, Lofano K, Piacentino G, De Tullio N, Ierardi E, Di Leo A. The fall of estrogen receptors expression in longlasting ulcerative-associated carcinoma. J Crohns Colitis 2013; 7: S15-S16 [DOI: 10.1016/S1873-9946(13)60036-7]
69. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-166 [PMID: 9927099 DOI: 10.1001/archinte.159.2.161]
70. Courtney ED, Melville DM, Leicester RJ. Review article: chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2004; 19: 1-24 [PMID: 14687163 DOI: 10.1046/j.1365-2036.2003.01806.x]
71. Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterol 2002; 97: 13-21 [PMID: 11808936 DOI: 10.1111/j.1572-0241.2002.05435.x]
72. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899 [PMID: 12621133 DOI: 10.1056/NEJMoa021735]
73. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-336 [PMID: 12891533 DOI: 10.1016/S0016-5085(03)00887-4]
74. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-174 [PMID: 11902503 DOI: 10.1016/S1470-2045(02)00680-0]
75. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 1998; 18: 78-84 [PMID: 9418855]
76. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959 [PMID: 8052854 DOI: 10.1126/science.8052854]
77. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153 [PMID: 10651654 DOI: 10.1046/j.1365-2036.2000.00698.x]
78. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32 [PMID: 8978339 DOI: 10.1016/S0016-5085(97)70215-4]
79. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95 [PMID: 11177311 DOI: 10.7326/0003-4819-134-2-200101160-00008]
80. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893 [PMID: 12671884 DOI: 10.1053/gast.2003.50156]
81. Giannini EG, Kane SV, Testa R, Savarino V. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? Dig Liver Dis 2005; 37: 723-731 [PMID: 16023905 DOI: 10.1016/j.dld.2005.02.012]
82. Egeberg R, Olsen A, Loft S, Christensen J, Johnsen NF, Overvad K, Tjønneland A. Intake of wholegrain products and risk of colorectal cancers in the Diet, Cancer and Health cohort study. Br J Cancer 2010; 103: 730-734 [PMID: 20733580 DOI: 10.1038/sj.bjc.6605806]
83. Kuijsten A, Hollman PC, Boshuizen HC, Buijsman MN, van 't Veer P, Kok FJ, Arts IC, Bueno-de-Mesquita HB. Plasma enterolignan concentrations and colorectal cancer risk in a nested case-control study. Am J Epidemiol 2008; 167: 734-742 [PMID: 18192676 DOI: 10.1093/aje/kwm349]
84. Milder IE, Kuijsten A, Arts IC, Feskens EJ, Kampman E, Hollman PC, Van 't Veer P. Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. J Nutr 2007; 137: 1266-1271 [PMID: 17449591]
85. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006; 147: 4831-4842 [PMID: 16809442 DOI: 10.1210/en.2006-0563]
86. Barone M, Tanzi S, Lofano K, Scavo MP, Pricci M, Demarinis L, Papagni S, Guido R, Maiorano E, Ingravallo G, Comelli MC, Francavilla A, Di Leo A. Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice. Carcinogenesis 2010; 31: 269-274 [PMID: 19945967 DOI: 10.1093/carcin/bgp275]
87. Seidlová-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol 2003; 86: 179-188 [PMID: 14568570 DOI: 10.1016/S0960-0760(03)00270-X]
88. El-Shitany NA, Hegazy S, El-Desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine 2010; 17: 116-125 [PMID: 19577454 DOI: 10.1016/j.phymed.2009.05.012]
89. Begum AN, Nicolle C, Mila I, Lapierre C, Nagano K, Fukushima K, Heinonen SM, Adlercreutz H, Rémésy C, Scalbert A. Dietary lignins are precursors of mammalian lignans in rats. J Nutr 2004; 134: 120-127 [PMID: 14704303]
90. Principi M, Di Leo A, Pricci M, Scavo MP, Guido R, Tanzi S, Piscitelli D, Pisani A, Ierardi E, Comelli MC, Barone M. Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study. World J Gastroenterol 2013; 19: 4325-4333 [PMID: 23885143 DOI: 10.3748/wjg.v19.i27.4325]
91. Calabrese C, Praticò C, Calafiore A, Coscia M, Gentilini L, Poggioli G, Gionchetti P, Campieri M, Rizzello F. Eviendep ® reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World J Gastroenterol 2013; 19: 5671-5677 [PMID: 24039360 DOI: 10.3748/wjg.v19.i34.5671]
92. Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. Fam Cancer 2013; 12: 707-718 [PMID: 23880960 DOI: 10.1007/s10689-013-9650-y]
93. Mill J, Lawrance IC. Prevention of cancer in IBD - a balancing act. Minerva Gastroenterol Dietol 2013; 59: 261-272 [PMID: 23867946]
94. Di Leo A, Linsalata M, Cavallini A, Messa C, Russo F. Sex steroid hormone receptors, epidermal growth factor receptor, and polyamines in human colorectal cancer. Dis Colon Rectum 1992; 35: 305-309 [PMID: 1582349 DOI: 10.1007/BF02048105]
95. Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 1-12 [PMID: 12476778 DOI: 10.2174/1568008013341749]